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Abstract
In patients undergoing surgical resection of brain metastases, the risk of local 
recurrence remains high. Adjuvant whole brain radiation therapy (WBRT) 
can reduce the risk of local relapse but fails to improve overall survival. At 
two tertiary care centers in Germany, a retrospective study was performed to 
evaluate the role of hypofractionated stereotactic radiotherapy (HFSRT) in 
patients with brain metastases after surgical resection. In particular, need for 
salvage treatment, for example, WBRT, surgery, or stereotactic radiosurgery 
(SRS), was evaluated. Both intracranial local (LF) and locoregional (LRF) 
failures were analyzed. A total of 181 patients were treated with HFSRT of 
the surgical cavity. In addition to the assessment of local control and distant 
intracranial control, we analyzed treatment modalities for tumor recurrence 
including surgical strategies and reirradiation. Imaging follow- up for the evalu-
ation of LF and LRF was available in 159 of 181 (88%) patients. A total of 
100 of 159 (63%) patients showed intracranial progression after HFSRT. A 
total of 81 of 100 (81%) patients received salvage therapy. Fourteen of 81 
patients underwent repeat surgery, and 78 of 81 patients received radiotherapy 
as a salvage treatment (53% WBRT). Patients with single or few metastases 
distant from the initial site or with WBRT in the past were retreated by 
HFSRT (14%) or SRS, 33%. Some patients developed up to four metachronous 
recurrences, which could be salvaged successfully. Eight (4%) patients expe-
rienced radionecrosis. No other severe side effects (CTCAE≥3) were observed. 
Postoperative HFSRT to the resection cavity resulted in a crude rate for local 
control of 80.5%. Salvage therapy for intracranial progression was commonly 
needed, typically at distant sites. Salvage therapy was performed with WBRT, 
SRS, and surgery or repeated HFSRT of the resection cavity depending on 
the tumor spread and underlying histology. Prospective studies are warranted 
to clarify whether or not the sequence of these therapies is important in terms 
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Introduction
Brain metastases are a significant cause of morbidity and 
mortality with an incidence of up to 40% during the 
trajectory of several cancer types [1, 2]. New treatment 
options have led to improved overall survival (OS) in 
selected patient groups; however, the median OS of 
3–6 months remains disappointing [3].
Surgery alone is known to be an effective treatment 
option for patients with a solitary brain metastasis, espe-
cially in those with neurological deficits. Microsurgical 
removal of metastases generally leads to complete remis-
sion of neurological symptoms [4]. In patients undergoing 
surgical resection of brain metastases, the risk of local 
recurrence without adjuvant therapy approaches 50–60% 
after 1 year [5]. Whole brain radiation therapy (WBRT) 
can significantly reduce the risk of local as well as locore-
gional relapse but fails to improve OS [5–8].
WBRT following surgery of a limited number (1–3) of 
brain metastases was found to have a negative impact on 
quality of life [9], especially in terms of impaired neu-
rocognitive functions [10–12]. Local irradiation of the 
tumor bed might be a promising treatment alternative 
leading to significantly less neurocognitive impairment 
[13] while still reducing the risk of local recurrence [14, 
15]. Even in patients with multiple brain metastases, the 
use of WBRT has become more controversial and restric-
tive over the last years [16, 17].
In Table 1, a literature overview of postoperative ste-
reotactic radiosurgery or stereotactic fractionated radio-
therapy is given.
A retrospective multicenter study (Department of 
Radiation Oncology, University Medical Center Freiburg 
and Department of Radiation Oncology, University 
Hospital Technical University Munich) was recently per-
formed to evaluate the role of hypofractionated stereotactic 
radiotherapy (HFSRT) in patients after surgical resection 
of ≤3 brain metastases. Local control (LC) after 12 months 
was 75%. The main advantages of HFSRT of the resec-
tion cavity in comparison with WBRT are the short treat-
ment time, the high probability of local control, and the 
reduced risk of normal tissue reactions including neuro-
cognitive impairment [13–15]. Detailed outcome data have 
already been presented elsewhere [18].
Importantly and in contrast to adjuvant WBRT, adjuvant 
HFSRT does not influence distant intracranial progression. 
Moreover, several dose prescription and fractionation concepts 
exist with different target volume guidelines [14, 15, 19, 20].
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Ahmed [24] 2014 65 20–30 5 87 89 65 12
Bilger [14] 2016 60 30–35 6–7 81.5 88.5 64.5 15
Do [31] 2009 30 22–27.5 4–6 82 87 51 13 (estimated)
Minniti [32] 2013 101 27 3 93 91 69 17
Specht [15] 2016 46 35 7 88 87 76 25
Steinmann [33] 2012 33 30–40 5–10 73 76 64 20
Ling [34] 2015 99 10–28 1–5 72 Not available 55 12
Wang [35] 2012 35 24 3 80 Not available Not available 6
SRS
Brennan [36] 2014 49 18 1 78 70 Not available Not available
Do [31] 2009 30 15–18 1 82 87 51 13 (estimated)
Hartford [37] 2013 47 12–20 1 86 66 52 13 (estimated)
Hwang [38] 2010 25 15–20 1 Not available 100 Not available 15
Iwai [39] 2008 21 13–20 1 82 76 Not available 20
Jagannathan [40] 2009 47 19 1 Not available 76 Not available 12
Jensen [41] 2011 106 17 1 80 87 47 11
Karlovits [42] 2009 52 15 1 82 82 Not available 15
Kelly [43] 2010 17 15–18 1 Not available 89 93 12
Limbrick [44] 2009 15 16–24 1 Not available 73 Not available 20
Luther [45] 2013 120 11–20 1 86 87 Not available Not available
Mathieu [46] 2008 40 16 1 Not available 73 Not available 13
Ogiwara [30] 2012 56 14–20 1 Not available 91 75 (estimated) 20
Prabhu [47] 2012 62 15–21 1–4 78 83 53 13
Soltys [48] 2008 65 18 1 79 86 57 15
Mahajan [20] 2017 64 12–16 1 72 76 ca. 70 17
Brown [19] 2017 98 20–24 1 60.5 Not available ca. 50 12
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For example, some centers use single- dose SRS as adju-
vant treatment and the dose prescription is depending 
on the size of the resection cavity [19, 20]. Others use 
HFSRT as adjuvant treatment, and the total dose is in 
some institutions depending on the absence or presence 
of residual tumor [14, 15].
It is therefore necessary to evaluate the feasibility of 
salvage therapy and the risk of side effects, especially in 
cases of reirradiation. In the present retrospective multi- 
institutional study, the patterns of intracranial local (LF) 
and locoregional (LRF) failure and the salvage treatment 
strategies for progression were evaluated.
Materials and Methods
Patient characteristics
We investigated 181 patients with newly diagnosed brain 
metastases who were treated with HFSRT following resec-
tion (July 2009 to November 2015) (see Table 1). Surgical 
resection was performed to palliate neurological dysfunc-
tions (e.g., seizures or motor deficits), intracranial pressure, 
or if the diameter of the lesion exceeded 3 cm. Patients 
prognosis was assessed according to the graded prognostic 
assessment (GPA) score and the recursive partitioning 
analysis (RPA) classes [21, 22].
Median age was 62 years (range 18–85 years), 99 (55%) 
patients were men, and 82 (45%) patients were women. 
The most common primary tumors were non- small- cell 
lung cancer (NSCLC) (36%), gastrointestinal cancer (16%), 
and breast cancer (15%). The patient characteristics are 
summarized in Table 2.
In our initial analysis [18], we evaluated LC, distant 
intracranial control, OS, and progression- free survival. 
Figure 1 shows two CMRIs of a patient treated with 
HFSRT before treatment and 4 years after treatment with-
out local progression.
The present analysis focused on individual treatment 
strategies after intracranial recurrence. We evaluated 
 different salvage therapies after local or locoregional 
recurrences.
The present work complies with the principles laid down 
in the Declaration of Helsinki and was approved by the 
appropriate ethical committees in both participating 
institutions.
Radiation therapy
Radiotherapy planning protocols of HFSRT to the resec-
tion cavity according to the different institutional standards 
were published before [14, 15].
Treatment planning—Munich
Individual fixation using a thermoplastic mask system for 
stereotactic setup was used for each patient with the 
Brainlab© mask system. For all patients, target volume 
definition was based on CT and MRI; generally, the post-
surgical MRI was used for treatment planning; a dedicated 
planning MRI was acquired in patients where the time 
interval between surgery and postoperative HFSRT 
exceeded 2 weeks [15]. The gross tumor volume (GTV) 
was defined as any residual tumor; the clinical target 
volume (CTV) consisted of the GTV and the resection 
cavity plus a safety margin of 2–3 mm accounting for 
Table 2. Patients’ characteristics.
n %
Age






Gastrointestinal cancer 28 15.5
Breast 29 16




Radioresistant tumors 27 14.9
Mean time from first diagnosis of primary 
tumor to first diagnosis of brain 
metastases (months)
33.5 (0–288)
Synchronous BM (0–1 months) 63 35
Metachronous BM (>1 month) 118 65
Resection status (MRI <48 h postop) 74
Complete resection 49 66.2
Residual tumor 25 33.8
Resection status (Planning MRI) 180
Complete resection 135 75













Mean resection cavity size (cm3)
16 (0.9–114.2)
Mean planning target volume size (cm3)
38.8 (3.5–205.1)
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potential microscopic spread. The PTV (planning target 
volume) was defined as the CTV expanded with a 1 mm 
margin. A median dose of 35 Gy in seven fractions (BED 
52.5 Gy, alpha/beta value 10 Gy), 5 Gy each was applied, 
with daily image- guided radiotherapy (IGRT) by robotic 
ExacTrac positioning (Brainlab, Germany) on a linear 
accelerator (LINAC) with a Micro- MLC (Varian, Palo 
Alto, CA) and 6 MeV photons.
Treatment planning—Freiburg
Patients were immobilized using a thermoplastic mask 
system. HFSRT target volume definition was based on 
CT and MRI [14]. In patients with residual/recurrent 
tumor, the GTV was delineated on contrast- enhanced MRI. 
Residual/recurrent tumor was defined as contrast enhance-
ment adjacent to the resection cavity. The CTV was defined 
as the contrast enhancement/GTV and resection cavity 
plus 1 mm. The PTV was defined as CTV expanded with 
a 2 mm margin. The treatment was delivered either by 
dynamic conformal arcs or by intensity- modulated radio-
therapy using a Varian TrueBeam STX Brainlab Novalis 
LINAC with 6 MeV photons. The median prescribed dose 
was 30 Gy in six fractions (BED 45 Gy, alpha/beta value 
10 Gy) in patients with complete tumor resection and 
35 Gy in seven fractions (52.5 Gy, alpha/beta value 10 Gy) 
in patients with residual/recurrent tumor after surgery.
Follow- up
All patients were followed up regularly including contrast- 
enhanced brain imaging as well as clinical follow- up, 
initially 6 weeks after treatment, then in 3- month intervals. 
After two years of recurrence- free follow- up, the intervals 
were prolonged individually. In case of local or distant 
intracranial failure, salvage therapy was performed after 
interdisciplinary discussion (neurosurgical intervention 
with/without adjuvant radiation therapy performed as 
WBRT or radiosurgery).
Endpoints
LF was defined as new contrast enhancement in the pre-
viously irradiated tumor bed or increasing residual/recur-
rent tumor volume in MRI. Radiation- induced changes 
(including radiation necrosis) were excluded based on 
serial follow- up and related clinical course. Lesions with 
increased contrast enhancement and edema after 6 weeks 
of treatment with corticosteroids and pentoxiflline for 
potential radiation- induced damage were classified as tumor 
progression; reduced edema and contrast enhancement 
were diagnosed as treatment- related changes/radiation 
necrosis. In case of severe neurological symptoms, an 
operation was performed to obtain a histological 
diagnosis.
Toxicities were classified as acute, if they occurred dur-
ing treatment or up to the first 6 weeks after the end of 
radiation. If they occurred later, toxicities were considered 
to be late toxicities. As neurocognitive impairment was 
not measured using standardized tests, it has not been 
included in this evaluation. Symptomatic brain necrosis 
was assessed by follow- up MRI and reviewed by a mul-
tidisciplinary team including the treating radiation oncolo-
gist, neurosurgeon, neuroradiologist, and pathologist. If 
there was a progressive, contrast- enhancing lesion and 
symptoms led to an impaired quality of life, surgical 
Figure 1. (A) Patient after resection of a renal cell carcinoma brain metastasis of the left temporal lobe. (B) The same patient 4 years after HFSRT of 
the resection cavity with complete remission.
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resection was performed after a consensus statement was 
obtained in an interdisciplinary tumor board. If histo-
pathological examination of the resection specimen revealed 
residual tumor, the case was considered as local recurrence. 
If not, it was considered as post- therapeutic brain necrosis. 
LRF was defined as new brain metastases or leptomeningeal 
enhancement outside the previously irradiated volume.
Statistics
The median follow- up time for analysis of OS was 
12.6 months after HFSRT of the resection cavity (range 
0.3–80.2 months). In 159 patients, follow- up imaging for 
the analysis of LC and PFS was available. The median 
follow- up time between the start of HFSRT and the last 
available cranial imaging was 10.7 months (range 1.1–
70.1 months). Data from both institutions were pooled 
in a dedicated database. All statistical calculations such 
as Kaplan–Meier analyses were performed using SPSS 
Statistics version 23 (IBM, New York, NY). A P- value 
≤ 0.05 was considered statistically significant.
Results
Crude local control after HFSRT of the resection cavity 
was 80.5%. Actuarial Kaplan–Meier analysis revealed a 
one- year local control rate of 75% and a two- year local 
control rate of 70% (Fig. 1 presents a patient`s resection 
cavity with 4- year event- free survival).
Female patients had a numerically higher local control 
rate than male patients (81% vs. 68%, P = 0.237).
Resection cavities >11.7 cm3 were at significantly 
increased risk of local recurrence (one- year local recur-
rence rate 68% vs. 82% for small cavities, P = 0.033). 
Detailed outcome data have already been presented else-
where [18].
Initial salvage treatment after HFSRT
A total of 100 of 159 (63%) evaluable patients experienced 
intracerebral tumor recurrence. Median time to the first 
intracranial recurrence was 5 months (6 LF, 73 LRF, 21 
LF+LRF).
At the time of first recurrence, 81 of 100 patients (81%) 
received salvage therapy. A total of 14 patients underwent 
repeat brain surgery, and 78 patients received repeat radio-
therapy. Of those, 41 patients with multiple (more than 
four) new brain metastases (53%) received WBRT. Patients 
with single or maximum four metastases distant from 
the site of initial HFSRT or a history of previous WBRT 
were retreated by HFSRT (14%) or stereotactic radiosur-
gery (SRS, 33%). Table 3 shows an overview of the salvage 
treatments.
Further salvage treatment
Forty- eight patients experienced a second intracranial fail-
ure. A total of 32 of 48 patients (67%) received further 
salvage therapy (10 WBRT, 18 SRS, and four HFSRT). 
Median time to second recurrence was 10 months (five 
LF, 38 LRF, and five LF+LRF).
Twelve patients developed a third failure (two LF, eight 
LRF, and two LF+LRF) after a median time of 14 months, 
and six of 12 (50%) had further radiotherapy (one WBRT, 
four SRS, and one HFSRT).
After a median time of 23 months, five patients had 
a fourth recurrence (three LRF and two LF+ LRF) and 
three of five (60%) had another salvage treatment (two 
WBRT and one SRS). Overall, three patients received five 
consecutive courses of radiotherapy.
A total of 54 of 159 patients (34%) eventually received 
WBRT during follow- up, 32 of 159 received another HSFRT 
(20%), and 33 of 159 (21%) received SRS as salvage 
treatment.
Salvage treatment of local recurrence
During follow- up, a total of 31 patients (19.5%) developed 
a local recurrence within the initial treatment field. Twenty- 
seven of 31 patients (87%) showed a local recurrence or 
a combined local and distant intracranial progression at 
first follow- up. Of those, 20 of 27 (74%) patients were 
effectively treated with salvage therapy. At the time of 
Table 3. Local failure and overview of salvage therapy in cases of recur-











100 48 12 5
Localization of tumor Recurrence (n)
LF 6 5 2
LRF 73 38 8 3
LF + LRF 21 5 2 2
Retreatment 
(n)
81 32 6 3
OP (+/−RTx) 14 (11/3)
RTx 78
WBRT 41 10 1 2
SRS 26 18 4 1
HFSRT 11 4 1
Time interval to 
initial HFSRT 
(months)
5 (1–27) 10 (2–42) 14 (11–55) 23 (14–28)
LF, local failure; LRF, locoregional failure; WBRT, whole brain radiother-
apy; SRS, stereotactic radiosurgery; HFSRT, hypofractionated stereotac-
tic radiotherapy.
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second intracranial recurrence, three new local recurrences 
occurred (10 in total, seven persisted after ineffective or 
omitted salvage therapy). A total of seven of 10 (70%) 
recurrences were salvaged successfully at the time of second 
recurrence. At the time of third intracranial failure, one 
more local recurrence (three patients with persisting local 
failure) occurred. Two of four (50%) recurrences were 
salvaged successfully. At the time of fourth intracranial 
recurrence, two patients showed persisting local recurrence; 
no new local recurrence occurred.
Overall, further radiation treatment was used as most 
common salvage strategy. Surgery was only used in case 
of severe symptoms from the metastases.
Eight (4%) patients in the whole cohort experienced 
radionecrosis at the initial treated resection cavity (single 
course of radiation). After steroid/pentoxiflline treatment 
showed no clinical benefit, in seven of those patients, the 
contrast- enhancing lesion was removed by neurosurgical 
intervention and the histopathological evaluation of the 
resected specimen showed only necrotic tissue and no sign 
of viable tumor cells. The mean PTV size of the seven 
patients with confirmed radionecrosis was 26.23 cm3 (range 
17.5–33.75 cm3) and was not bigger than the mean PTV 
of all patients included in the study (mean 38.8 cm3, range 
3.5–205.1 cm3). Three of these patients had breast cancer, 
one had a renal cell carcinoma, one had rectum carcinoma, 
one had lung cancer, and one had a thymus carcinoma 
as primary tumor. After operation of the radionecrosis, 
five of seven (71%) patients died during follow- up. The 
mean time from operation of the radionecrosis to death 
was 14.4 months (range 7–27 months), which means that 
surgery was successful in preventing death from 
radionecrosis.
No other cases of severe treatment- related side effects 
(CTCAE≥3) were observed. Especially, no bleedings or 
seizures occurred.
Discussion
At two tertiary care centers in Germany, we performed 
a retrospective study to evaluate the role of hypofraction-
ated stereotactic radiotherapy (HFSRT) in patients with 
brain metastases after surgical resection. Local control 
(LC) after 12 months was 75% [18]. In the present analy-
sis, we focused on salvage therapy of brain metastases in 
case of intracranial progression after HFSRT of the resec-
tion cavity. We were interested in finding out whether 
or not salvage treatment after HFSRT is possible without 
leading to a high risk of radiation necrosis. In particular, 
need for salvage treatment, for example, WBRT, surgery, 
or stereotactic radiosurgery (SRS), was evaluated. Both 
intracranial local (LF) and locoregional (LRF) failure were 
analyzed.
A total of 100 of 159 (63%) patients received salvage 
therapy (surgery with or without adjuvant radiation ther-
apy, WBRT, and SRS). Local failures were rare, and distant 
intracranial failures were often effectively salvaged by 
further radiotherapy. Even most local failures were salvaged 
successfully.
Previously, we have shown that postoperative HFSRT 
to the resection cavity in patients with brain metastases 
is a highly effective concept, leading to satisfactory long- 
term local control after surgery. Our data for local control 
were even better than in the two prospective studies 
published in 2017 about radiation therapy of the resection 
cavity [19, 20] (see Table 1, literature overview). Many 
reasons might explain this fact, including significant dif-
ferences in target volume definition with respect to safety 
margins for the CTV. The most recent randomized trials 
offered radiosurgery, with very small to no safety margins 
accounting for microscopic spread [19, 20]. In our mul-
ticenter setting, both groups applied at least 2–3 mm 
safety margins from GTV to CTV. This might have con-
tributed to the higher rate of local control observed in 
our study.
New guidelines for contouring for postoperative cavity 
SR/HFSRT are needed. Soliman et al. have tried to find 
a consensus for contouring, but clinical data to support 
these recommendations are still missing [23]. For certain 
histologies, the fractionated concept, albeit hypofraction-
ated, is also more promising in terms of radiation biology 
compared to the single- dose approach reported by others 
[24].
On the other hand, as this is a retrospective analysis, 
it appears possible that prospective follow- up depicts more 
failures, and other sources of selection bias are possible, 
too.
It has been shown previously that male sex and large 
resection cavity size (>11.7 cm3) are predictors for inferior 
overall local control [18]. Therefore, in future prospective 
trials, a higher dose for large cavity sizes might be dis-
cussed. However, large volume bears a higher risk for 
radiation- related side effects which must be kept in might 
in those considerations. As also previously shown, there 
was a trend toward earlier intracerebral progression if the 
first diagnosis of brain metastases was synchronous to 
the first diagnosis of the primary tumor. For patients 
with more than one brain metastasis at the time of HSFRT, 
there was also a tendency toward earlier intracerebral 
recurrence.
The data in the present manuscript suggest that, after 
local multimodal therapy for brain metastases (surgery + 
local RT), WBRT can be deferred without compromising 
survival. As WBRT may reduce neurocognitive function, 
leading to worsening of quality of life, without improving 
OS [5–8], WBRT can be withheld and performed in cases 
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of multiple new metastases. Previously, Gorovets et al. 
published a nomogram to predict the time between SRS 
and WBRT salvage treatment [25]. Also, in case of HFSRT, 
this nomogram could be used to decide which patients 
benefit most of HFSRT to the resection cavity instead of 
WBRT, if further studies confirm its validity in this set-
ting. Even in patients with multiple brain metastases, 
standard WBRT could be replaced by WBRT with hip-
pocampal sparing, depending on expected survival, in 
order to reduce toxicity [26].
Decision- making requires thorough assessment of the 
patients’ general state of health and expected survival. 
Some patients with multiple brain metastases and terminal 
illness will not benefit from WBRT because they are in 
a very palliative situation [27]. Newer review articles and 
articles about risk analysis of distant brain failures after 
radiosurgery could support decision- making [16, 17]. In 
general, a trend toward a more restrictive use of WBRT 
in favor of local treatment with SRS even in patients 
with multiple brain metastases is seen, but also socioeco-
nomic and racial/ethnic disparities in the use and uptake 
of SRS in the USA [28].
As we performed a retrospective study, the decision about 
the modality of salvage therapy (SRS/surgery or WBRT) 
was made by the physician in charge. In general, patients 
with single or maximum four metastases distant from the 
site of initial HFSRT or a history of previous WBRT were 
retreated by HFSRT or SRS. However, it might be possible 
that also patients in good clinical condition with >4 metas-
tases distant from the site of initial treatment could benefit 
from a localized SRS as salvage therapy.
Although, in HFSRT, the irradiated volume is bigger 
compared to SRS, repeated radiotherapy or surgery did 
not lead to a high rate of radionecrosis in our study.
Due to the high rate of distant intracranial relapse, 
regular follow- up with MRI is mandatory. Whether this 
strategy of repeat imaging and treatment results in cost- 
effectiveness and a satisfactory number of quality- adjusted 
life years compared to up- front WBRT remains to be 
established.
As we have shown in this analysis deferred salvage with 
WBRT/SRS and surgery is feasible and appears also safe 
and efficient, but discrimination between recurrence and 
treatment- induced side effects is sometimes challenging 
and often requires additional imaging. Furthermore, a 
retrospective study cannot capture all aspects of brain 
toxicity. In addition, short follow- up and early death events 
may decrease the apparent risk of late toxicity [29]. Despite 
these caveats, even patients with four salvage radiation 
treatments had no excessive risk of radiation necrosis.
In an analysis by Ogiwara et al. [30], who looked at 
patterns of recurrence after SRS to the resection cavity, 
similar results concerning salvage treatments were found, 
but our work represents the largest cohort (two German 
institutions) to our knowledge in the literature. Prospective 
studies concerning HFSRT of the resection cavity are cur-
rently being carried out, which will shade more light on 
subsequent treatment utilization and sequelae.
Tailored salvage treatment after HFSRT to the resection 
cavity using SRS, WBRT, or surgery appears safe and 
efficient. As toxicity was recorded retrospectively and 
without capturing all domains, prospective studies are 
warranted. Currently, the LAUREL study at the Technical 
University of Munich (TUM) is evaluating toxicity and 
outcome regarding imaging response, patterns of failure, 
and survival in patients with brain metastases treated with 
HFSRT. Due to the high rate of distant intracranial failure 
after local multimodal therapy for brain metastases, regular 
follow- up with MRI is mandatory.
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